Humans ; Lymphoma, T-Cell, Peripheral ; diagnosis ; therapy

Humans ; Lymphoma, T-Cell, Peripheral ; diagnosis ; therapy ; Translational Medical Research

Angiocentric T cell lymphoma is a variant of peripheral T cell lymphoma characterized by an angiocentric and angioinvasive infiltrates, invasion of vascular walls, and occulsion of lumen by atypical lymphoid cells with varying degrees of cytologic atypia. We recently experienced a woman with angiocentric T cell lymphorma, who presented with multiple erythematous nodules of skin, subcutaneous mass on right face and peripheral polyneuropathy. At the skin biopy specimen, we could find angiocentric and angioinvasive infiltrate by atypical lymphoid cells which showed a positive immunohistochemical reaction for CD45RO that is one of the T cell markers and a negative reaction for B cell marker. She was treated with two cycles of combination chemotherapy composed of CVP (cyclophosphamide, vincristine, prednisolone), that resulted in complete remission.
Drug Therapy, Combination ; Female ; Humans ; Lymphocytes ; Lymphoma, T-Cell* ; Lymphoma, T-Cell, Peripheral ; Polyneuropathies* ; Skin ; Vincristine

Angiocentric T-cell lymphoma is a subtype of peripheral T-cell lymphoma and histologically characterized by angiocentric and angioinvasive infiltration of lymphoid cells with varying degrees of cytological atypia, leading to angiodestruction. This disease represents the malignant end in the histological spectrum of angiocentric immunproliferative lesions. This malignancy is commonly a disease with considerable morbidity and is often fatal. However, primary cutaneous angiocentric T-cell lymphoma has a tendency to give a favorable prognosis. Epstein-Barr virus can be identified in involved tissue by immunostaining or by in situ hybridization and it is considered significant in the prognosis. We report a case of cutaneous angiocentric T-cell lymphoma, where the Epstein-Barr virus was identified within neoplastic cells. CVP(cyclophosphamide, vincristine, prednisone) chemotherapy was instigated and an initial complete remission was achieved.
Drug Therapy* ; Herpesvirus 4, Human ; In Situ Hybridization ; Lymphocytes ; Lymphoma, T-Cell* ; Lymphoma, T-Cell, Peripheral ; Prognosis ; T-Lymphocytes* ; Vincristine

A case of peripheral T-cell lymphoma, large cell type(NIH) is reported. The literature review yielded a rare case report of a malignant lymphoma especially in the even more rare epidural site. The patient's symptoms were relieved by decompressive laminectomy and subtotal removal of mass and combined scheduled chemotherapy with radiotherapy. The pathological examination revealed malignant lymphoma, diffuse, large cell type(NIH) by H & E and immunologic marker analysis.
Biomarkers ; Drug Therapy ; Epidural Space* ; Laminectomy ; Lymphoma ; Lymphoma, T-Cell, Peripheral* ; Radiotherapy

Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, T-Cell, Peripheral ; therapy ; Transplantation, Homologous

A 72-year-old male presented with respiratory discomfort. A simple chest X-ray and abdominal computed tomography showed pleural effusion and multiple lymph node enlargement. The pleural effusion was determined by thoracentesis to be chylothorax. An inguinal lymph node biopsy showed peripheral T-cell lymphoma. Following three cycles of cyclophospamide, hydroxyl doxorubicin, vincristine, prednisolone (CHOP) chemotherapy, a partial response was observed. Chylothorax is an extremely rare complication of T-cell lymphoma. We present a case of peripheral T-cell lymphoma presenting with chylothorax. We suggest that clinicians should consider chylothorax when examining patients with lymphoma who present with atypical pleural effusion.
Aged ; Biopsy ; Chylothorax* ; Doxorubicin ; Drug Therapy ; Humans ; Lymph Nodes ; Lymphoma ; Lymphoma, T-Cell ; Lymphoma, T-Cell, Peripheral* ; Male ; Pleural Effusion ; Prednisolone ; Thoracentesis ; Thorax ; Vincristine

Accurate diagnosis of autoimmune pancreatitis (AIP) is important to clinicians since it is difficult to differentiate AIP from pancreatic malignancies. Furthermore, unlike pancreatic malignancies, AIP has dramatic response to steroids. A 61-years-old man presented with acute pancreatitis. Imaging studies showed two separate pancreatic masses, irregular narrowing of main pancreatic duct, and a renal mass that highly suggested AIP. Endoscopic ultrasound-guided core needle biopsy of the pancreatic masses and ultrasound-guided biopsy of the renal mass revealed peripheral T-cell lymphoma. The patient is currently undergoing chemotherapy. We present a case of pancreatic lymphoma masquerading as AIP with literature review.
Biopsy ; Biopsy, Large-Core Needle ; Diagnosis ; Drug Therapy ; Humans ; Lymphoma* ; Lymphoma, T-Cell, Peripheral ; Pancreatic Ducts ; Pancreatic Neoplasms ; Pancreatitis* ; Steroids

BACKGROUND: Among pediatric non-Hodgkin lymphomas, there are 4 major subtypes: Burkitt lymphoma, lymphoblastic lymphoma, diffuse large B-cell lymphoma, and anaplastic large-cell lymphoma. Understanding of other rare subtypes derives only from small pediatric case series. We report our institutional experience with rare pediatric NHLs.METHODS: Thirty-six cases of rare NHL subtypes diagnosed at the Asan Medical Center from 1995 to 2015 were evaluated. We retrospectively reviewed the clinical and pathologic features and outcomes of these patients, excluding peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), and extranodal NK/T-cell lymphoma (ENKL), on which we have previously reported.RESULTS: There were 23 cases of T-cell lineage (13 PTCL, 6 ENKL, 2 subcutaneous panniculitis-like T-cell lymphoma, 1 primary cutaneous CD4+2016-11-22 small/medium sized T-cell lymphoma, 1 enteropathy-associated T-cell lymphoma) and 13 cases of B-cell lineage lymphoma (5 marginal zone lymphoma, 6 primary mediastinal large B-cell lymphoma, 2 immunoblastic and plasmablastic lymphoma). All patients were treated with chemotherapy with or without surgery, except 4 out of 5 patients with marginal zone lymphoma who received surgery only. Two patients died and 6 patients relapsed. One patient with primary mediastinal large B-cell lymphoma received autologous peripheral blood stem cell transplantation. The 5-year overall survival and event-free survival rates of rare pediatric NHL excluding PTCL, NOS, and ENKL was 80.0% and 72.0%, respectively.CONCLUSION: Children diagnosed with rare pediatric NHL other than PTCL, NOS, and ENKL showed variable incidence and treatment outcomes. Multicenter studies in larger cohorts are needed for better understanding of these rare NHL subtypes in childhood.
B-Lymphocytes ; Burkitt Lymphoma ; Child ; Chungcheongnam-do ; Cohort Studies ; Disease-Free Survival ; Drug Therapy ; Humans ; Incidence ; Lymphoma ; Lymphoma, B-Cell ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell ; Lymphoma, T-Cell, Peripheral ; Peripheral Blood Stem Cell Transplantation ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Retrospective Studies ; T-Lymphocytes

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is a rare form of non-Hodgkin's lymphoma (NHL), and it is usually associated with poor outcome. Here, we report our experience in treating this disease over 19 years, with the aim of helping to establish better treatment methods.METHODS: We retrospectively investigated 18 non-anaplastic PTCL cases that were diagnosed at a medical center in Seoul between October 1995 and October 2014. The clinical characteristics, treatments, and outcomes were reviewed.RESULTS: According to the World Health Organization (WHO) classifications for PTCL, 11 patients had PTCL, not otherwise specified (PTCL-NOS), 6 patients had extranodal natural killer/T-cell lymphoma, nasal type (ENKL), and 1 patient had subcutaneous panniculitis-like T-cell lymphoma. Patients were treated with various chemotherapeutic regimens. Of these 18 patients, 5 (27.7%) relapsed and 7 (38.9%) died from disease progression. Two relapsed patients received high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT-ASCT). The 5-year event-free and overall survival rates were 43.2% and 66.7% in all cases, 45.5% and 54.5% in PTCL-NOS, and, 25.0% and 83.3% in ENKL, respectively.CONCLUSION: PTCL-NOS showed a suboptimal outcome. Among 6 ENKL patients, 3 relapsed, but 2 of 3 relapsed patients were salvaged. For better prognosis, HDCT-ASCT in relapsing and refractory PTCL and chemo-radiotherapy in ENKL could be considered as a salvage treatment. Larger studies are needed to confirm the outcome. Furthermore, an effort should be made to develop more efficient initial therapies through collaborative research.
Adolescent ; Child ; Classification ; Disease Progression ; Drug Therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell ; Lymphoma, T-Cell, Peripheral ; Prognosis ; Retrospective Studies ; Seoul ; Survival Rate ; T-Lymphocytes ; World Health Organization